Chardan Capital Downgrades Tenax Therapeutics to Neutral, Lowers Price Target to $5
Benzinga Newsdesk 2 months ago
NewsDowngradesAnalyst RatingsPrice Target
Chardan Capital analyst Gautam Chukka downgrades Tenax Therapeutics (NASDAQ:TENX) from Buy to Neutral and lowers the price target from $27 to $5.
Chardan Capital analyst Gautam Chukka downgrades Tenax Therapeutics (NASDAQ:TENX) from Buy to Neutral and lowers the price target from $27 to $5.